Clinical Research Directory
Browse clinical research sites, groups, and studies.
Outcomes in Bone Marrow Aplasia.
Sponsor: Assiut University
Summary
Bone marrow aplasia, also known as aplastic anemia (AA) is a potentially fatal bone marrow failure syndrome characterized by a paucity of hematopoietic stem cells (HSCs) and progenitor cells with varying degrees of cytopenia and fatty infiltration of the bone marrow space. Underlying mechanisms include immune-mediated attack, telomere defects, and inherent HSC compartment insufficiency. These events may occur individually or in concert, mostly involving effector T cells Historical treatment has included the use of high-dose chemotherapy and allogeneic stem cell transplantation as well as lymphotoxic immunosuppressive therapy (IST) Thrombopoietin (TPO) regulates platelet production, maturation, and release through binding of c-mpl on megakaryocytes.
Official title: Long Term Outcomes of Eltrombopag in Patients With Bone Marrow Aplasia, Assiut University Hospital Insight.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
3
Start Date
2024-07
Completion Date
2030-07
Last Updated
2024-07-10
Healthy Volunteers
Yes
Conditions
Interventions
Eltrombopag
Treatment with eltrombopag in a dose of (50-150mg/d)